Hepatocellular Carcinoma.
Conditions
Interventions
Sponsors
Shanghai Tenth People' Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Male or non-pregnant women aged 18-80 years old; 2. Hepatocellular carcinoma diagnosed according to EASL standard (single lesion = 8cm or up to 3 lesions = 3cm); 3. According to the primary diagnosis and treatment of liver cancer (2017 edition) clinical stage of Ib, IIa HCC; 4. ECOG score = 2; 5. No history of chemotherapy, radiotherapy or embolism nearly 2 months; 6. No vascular infiltration or extrahepatic proliferation; 7. Good liver function (Child-Pugh A-Child-Pugh B); 8. Patients are able to understand the purpose of the trial, sign informed consent voluntarily, and agree to undergo a 6-month follow-up of imaging.
Exclusion criteria
Exclusion criteria: 1. The investigators believe that patients who are not fit to participate in this trial; 2. Pregnancy and lactation in female patients; 3. Platelet 2mg/dl or creatinine clearance 3mg/dl; 12. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)> 5 × ULN (upper limit of normal) or> 250 IU / L, = 2 × ULN after 1 week of liver and antiviral treatment; 13. Patients with uncontrollable or obvious heart disease, such as congestive heart failure, difficult to control supraventricular or ventricular arrhythmias, class II or more atrioventricular block, acute myocardial ischemia or prolonged QT interval, or myocardial infarction in the past 6 months; 14. Patients who have participated in other drug or instrumental clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate;Surgical success rate;the incidence of treatment-related serious adverse events;the change of tumor marker AFP; | — |
Countries
China
Contacts
Public ContactMaoquan Li
Shanghai Tenth People' Hospital
Outcome results
None listed